pilaralisib
Small moleculeexperimental
Clinical trial activity
13 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
12
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2007 (NCT00486135)
Timeline
Indications
Mechanism of action
- PI3-kinase class IINHIBITOR
PI3-kinase class I inhibitor
- Phosphatidylinositol 3-kinase regulatory subunit alpha (PIK3R1) ↗
- Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform (PIK3CB) ↗
- Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform (PIK3CG) ↗
- Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (PIK3CA) ↗
- Phosphatidylinositol 3-kinase regulatory subunit beta (PIK3R2) ↗
- Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform (PIK3CD) ↗
- Phosphoinositide 3-kinase regulatory subunit 5 (PIK3R5) ↗
- Phosphatidylinositol 3-kinase regulatory subunit gamma (PIK3R3) ↗
- PI3-kinase p85-alpha subunit
- PI3-kinase p110-delta subunit
- PI3-kinase p110-alpha subunit
- PI3-kinase p110-gamma subunit
- PI3-kinase p110-beta subunit
- PI3-kinase p85-beta subunit
- PI3-kinase p110-delta/p85-alpha
- PI3-kinase p110-alpha/p85-alpha
- PI3K p110 beta/p85 alpha
- PI3-kinase subunit gamma/Phosphoinositide 3-kinase regulatory subunit 5
- Phosphatidylinositol 3-kinase regulatory subunit beta/Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform
- Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform/gamma isoform
- PIK3CG/PIK3R1
- Phosphatidylinositol 3-kinase regulatory subunit gamma
Chemistry & pharmacology
Loading structure…
SMILES
COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)C(C)(C)N)c2)c1- Mol. weight
- 541.03 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3360203 ↗
Also known as
- pilaralisib
- pilaralisib
- pilaralisib
- sar245408
- sar245408
- sar245408
- sar 245408
- sar-245408
- sar-245408
- xl147
- xl147
- xl147
- xl-147
- xl-147
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01943838 | Phase 1 | Oct 1, 2013 | Sanofi |
| NCT01587040 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2012 | Sanofi |
| NCT01436565 | Phase 1 | Nov 1, 2011 | Merrimack Pharmaceuticals, Sanofi |
| NCT01392924 | Phase 1 | Aug 1, 2011 | Sanofi |
| NCT01357330 | Phase 1 | May 1, 2011 | Sanofi |
| NCT01240460 | Phase 1 | Jan 1, 2011 | Sanofi |
| NCT01082068 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2010 | Sanofi |
| NCT01042925 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2010 | Sanofi |
| NCT01013324 | Phase 2 | Jan 1, 2010 | Sanofi |
| NCT00756847 | Phase 1 | Sep 1, 2008 | Sanofi |
| NCT00704392 | Phase 1 | Jun 1, 2008 | Exelixis |
| NCT00692640 | Phase 1 | May 1, 2008 | Sanofi |
| NCT00486135 | Phase 1 | Jun 1, 2007 | Sanofi |
Showing 13 of 13 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sanofi | For profit | 12 | 12 | 2 | 2007 |
| Exelixis | For profit | 1 | 1 | 1 | 2008 |
| Merrimack Pharmaceuticals | For profit | 1 | 0 | 1 | 2011 |
3 organizations
Page 1 / 1